Lv4
660 积分 2025-07-09 加入
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
1天前
已完结
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study
15天前
已关闭
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
27天前
已完结
Prostate-Specific Membrane Antigen PET-Guided Salvage Radiotherapy—Precision or Prematurity?
1个月前
已关闭
Should We Embark on “EMBARK”? Reassessing the Role of Radiotherapy and Androgen Receptor Pathway Inhibitors in the Era of Next-generation Imaging
1个月前
已完结
A risk-adjusted definition of biochemical recurrence after radical prostatectomy
1个月前
已完结
Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival
1个月前
已完结
Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review
1个月前
已完结
Surgery with or Without Darolutamide in High-risk and/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol
1个月前
已完结
Management of Metastatic Prostate Cancer
2个月前
已完结
皖公网安备34019202002308
